InterCure Strengthens Position In Cannabis Market With New Private Placement        

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR), which does business as Canndoc, has obtained NIS 22 million ($7.4 million) in committed funding through a private placement.

What Happened

Under the transaction, the shares are being issued at NIS 2.75 per share, above the recent market closing price of NIS 2.69.

Moreover, investors are to receive warrants exercisable over a five-year period to purchase up to an additional 7,895,143 ordinary shares of the company at NIS 4.125 per share, about 53% above the reference market price.

Why It Matters

The company plans to use the funds to rebuild and expand its Nir Oz facility to meet increasing demand in Israel and international markets, boost global expansion, particularly in Germany, and pursue opportunities emerging from recent U.S. cannabis regulatory changes, CEO Alexander Rabinovich said in a press release.

He called the financing an important step in the company’s recovery and growth strategy.

If investors fully exercise accompanying warrants, the financing could potentially expand to NIS 54 million.

“The participation of certain of our existing shareholders, together with leading pharma-focused investment funds, reflects strong confidence in InterCure’s business model, market position and long-term growth potential,” Rabinovich said in a press release.

What’s Next

With this financing and the expected recovery of war-related damages, InterCure is better positioned to accelerate its recovery, pursue growth opportunities, and achieve sustainable profitability while serving patients, partners, and shareholders, Rabinovich explained.

INCR Price Action

InterCure’s shares traded 23.38% higher at $1.14 per share at the time of writing on Monday.